These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Inhibition of platelet activation by peptide analogs of the beta(3)-intracellular domain of platelet integrin alpha(IIb)beta(3) conjugated to the cell-penetrating peptide Tat(48-60). Dimitriou AA; Stathopoulos P; Mitsios JV; Sakarellos-Daitsiotis M; Goudevenos J; Tsikaris V; Tselepis AD Platelets; 2009 Dec; 20(8):539-47. PubMed ID: 19863457 [TBL] [Abstract][Full Text] [Related]
28. The serine protease granzyme A does not induce platelet aggregation but inhibits responses triggered by thrombin. Suidan HS; Clemetson KJ; Brown-Luedi M; Niclou SP; Clemetson JM; Tschopp J; Monard D Biochem J; 1996 May; 315 ( Pt 3)(Pt 3):939-45. PubMed ID: 8645180 [TBL] [Abstract][Full Text] [Related]
29. KRDS, a peptide derived from human lactotransferrin, inhibits thrombin-induced thromboxane synthesis by a cyclooxygenase-independent mechanism. Lévy-Toledano S; Grelac F; Caen JP; Maclouf J Thromb Haemost; 1995 May; 73(5):857-61. PubMed ID: 7482416 [TBL] [Abstract][Full Text] [Related]
30. PPACK-thrombin inhibits thrombin-induced platelet aggregation and cytoplasmic acidification but does not inhibit platelet shape change. Greco NJ; Tenner TE; Tandon NN; Jamieson GA Blood; 1990 May; 75(10):1989-90. PubMed ID: 2337670 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of thrombin-catalyzed factor V activation by bothrojaracin. Arocas V; Lemaire C; Bouton MC; Bezeaud A; Bon C; Guillin MC; Jandrot-Perrus M Thromb Haemost; 1998 Jun; 79(6):1157-61. PubMed ID: 9657441 [TBL] [Abstract][Full Text] [Related]
32. Synthetic alpha-thrombin receptor peptides activate G protein-coupled signaling pathways but are unable to induce mitogenesis. Vouret-Craviari V; Van Obberghen-Schilling E; Rasmussen UB; Pavirani A; Lecocq JP; Pouysségur J Mol Biol Cell; 1992 Jan; 3(1):95-102. PubMed ID: 1312881 [TBL] [Abstract][Full Text] [Related]
33. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Kuliopulos A; Covic L; Seeley SK; Sheridan PJ; Helin J; Costello CE Biochemistry; 1999 Apr; 38(14):4572-85. PubMed ID: 10194379 [TBL] [Abstract][Full Text] [Related]
34. Thrombin receptor-mediated vascular relaxation differentiated by a receptor antagonist and desensitization. Tesfamariam B Am J Physiol; 1994 Nov; 267(5 Pt 2):H1962-7. PubMed ID: 7526715 [TBL] [Abstract][Full Text] [Related]
35. Developing peptide inhibitors to thrombin activation of platelets from bradykinin analogs. Hasan AA; Warnock M; Srikanth S; Schmaier AH Thromb Res; 2001 Dec; 104(6):451-65. PubMed ID: 11755956 [TBL] [Abstract][Full Text] [Related]
36. Characteristics of the interaction between thrombin exosite 1 and the sequence 269-287 [correction of 269-297] of platelet glycoprotein Ibalpha. Bouton MC; Thurieau C; Guillin MC; Jandrot-Perrus M Thromb Haemost; 1998 Aug; 80(2):310-5. PubMed ID: 9716158 [TBL] [Abstract][Full Text] [Related]
37. Thrombin receptor peptide inhibits thrombin-induced increase in endothelial permeability by receptor desensitization. Lum H; Andersen TT; Siflinger-Birnboim A; Tiruppathi C; Goligorsky MS; Fenton JW; Malik AB J Cell Biol; 1993 Mar; 120(6):1491-9. PubMed ID: 8383691 [TBL] [Abstract][Full Text] [Related]
38. The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation. Bahou WF; Coller BS; Potter CL; Norton KJ; Kutok JL; Goligorsky MS J Clin Invest; 1993 Apr; 91(4):1405-13. PubMed ID: 8386186 [TBL] [Abstract][Full Text] [Related]